Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Other research analysts have also issued reports about the company. Citigroup reissued a “buy” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 15th. Maxim Group decreased their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Roth Capital reissued a “buy” rating and set a $3.00 target price (down from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Chardan Capital started coverage on Reviva Pharmaceuticals in a report on Monday, September 29th. They issued a “buy” rating and a $2.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Saturday, September 27th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $4.86.

Reviva Pharmaceuticals Stock Up 11.7%

Shares of Reviva Pharmaceuticals stock opened at $0.55 on Friday. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $4.28. The stock has a market cap of $37.79 million, a P/E ratio of -0.84 and a beta of -0.08. The business’s 50 day moving average is $0.44 and its 200-day moving average is $0.63.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. On average, sell-side analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Trading of Reviva Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter worth $1,026,000. 683 Capital Management LLC bought a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter worth $381,000. Persistent Asset Partners Ltd lifted its position in shares of Reviva Pharmaceuticals by 300.0% during the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after buying an additional 480,864 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Reviva Pharmaceuticals during the 1st quarter worth $191,000. Finally, XTX Topco Ltd bought a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter worth $31,000. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.